AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Imugene has dosed the first Australian patient in its Phase 1b azer-cel clinical trial at Sydney's Royal Prince Alfred Hospital.
- U.S. cohort results showed three patients achieved complete responses (CR) despite previous treatment relapses.
- Patients in cohort B demonstrated robust and durable responses, with durations extending beyond 90 and 120 days.
Imugene Limited (ASX:IMU) has reached a significant milestone in its Phase 1b azer-cel clinical trial. The first Australian patient has been dosed in the trial of the allogeneic CAR T-cell therapy azercabtagene zapreleucel (azer-cel) at the Royal Prince Alfred Hospital (RPAH) in Sydney.
The open-label, multi-centre study targets individuals with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive subtype of non-Hodgkin’s lymphoma.
Promising Data from U.S. Trials
The Australian dosing follows encouraging results from the US trial sites, which highlighted the potential of azer-cel to achieve significant clinical outcomes. In the US trials, three patients achieved complete responses (CR) despite undergoing multiple previous treatments, including autologous CAR T-cell therapy.
Particularly notable were the outcomes in Cohort B, where patients were dosed with lymphodepletion chemotherapy and interleukin-2 (IL-2). These participants demonstrated robust and long-lasting responses, with some extending beyond 90 and 120 days.
About azer-cel
Azer-cel is among the select few allogeneic CAR T-cell therapies under evaluation in Australia. Unlike traditional autologous CAR T-cell therapies, which involve long manufacturing processes (as it utilises patient’s own cells), azer-cel provides an off-the-shelf alternative. It utilises pre-manufactured donor T-cells, potentially resulting in considerable reduction in treatment timelines and improvement in accessibility for patients with limited therapeutic options.
IMU share price jumped
At the time of writing on 3 January 2025, IMU share price increased by 5.13% to AU$0.041 per share.
